Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center

Background Real‐world data of the CM regimen [cyclophosphamide (CTX) plus methotrexate (MTX)] in metronomic pattern for advanced breast cancer is limited to small‐sample or retrospective studies. This study was aimed to determine the effectiveness and safety of CM regimen in treating advanced breast...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer communications (London, England) England), 2020-05, Vol.40 (5), p.222-233
Hauptverfasser:	Lu, Qianyi, Lee, Kaping, Xu, Fei, Xia, Wen, Zheng, Qiufan, Hong, Ruoxi, Jiang, Kuikui, Zhai, Qinglian, Li, Yuan, Shi, Yanxia, Yuan, Zhongyu, Wang, Shusen
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Metronomic Adult advanced breast cancer Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer therapies Chemotherapy Clinical medicine Clinical trials Confidence intervals cyclophosphamide Cyclophosphamide - administration & dosage Data Analysis Disease control Drug Administration Schedule Drug dosages Endocrine therapy Epidermal growth factor Estrogens Humans Kaplan-Meier Estimate Life Sciences & Biomedicine Medical prognosis Metastasis methotrexate Methotrexate - administration & dosage metronomic chemotherapy Middle Aged Multivariate Analysis Oncology Original Radiation therapy real‐world Response rates Retrospective Studies Science & Technology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background Real‐world data of the CM regimen [cyclophosphamide (CTX) plus methotrexate (MTX)] in metronomic pattern for advanced breast cancer is limited to small‐sample or retrospective studies. This study was aimed to determine the effectiveness and safety of CM regimen in treating advanced breast cancer and to identify which patients are most likely to benefit from metronomic CM regimen. Methods Patients with advanced breast cancer who received the metronomic CM regimen at least once between January 2009 and February 2019 in Sun Yat‐sen University Cancer Center were included. Clinicopathological characteristics were collected. Overall survival (OS) and progression‐free survival (PFS) were assessed using Kaplan‐Meier estimates. Characteristics between patients with PFS
ISSN:	2523-3548 2523-3548
DOI:	10.1002/cac2.12029